---
document_datetime: 2023-09-21 18:46:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/tamiflu-epar-procedural-steps-taken-authorisation_en.pdf
document_name: tamiflu-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3569654
conversion_datetime: 2025-12-23 03:43:20.380148
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Roche Registration Limited submitted on 9 February 2001 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Tamiflu, through the centralised procedure. After agreement by the CPMP on 27 January 1999, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr. Pekka Kurki

## Scientific Advice:

The  applicant  received  Scientific  Advice  from  the  CPMP  on  25  June  1998.  The  Scientific  Advice pertained to part IV of the dossier.

## Licensing status:

Tamiflu has been given a Marketing Authorisation in U.S.A (27/10/99, 17/11/00, 14/12/00), Canada (23/12/99), Russia (10/07/00), Japan (12/12/00), Australia (13/09/00) and 27 additional countries.

## 2. Steps taken for the assessment of the product

- The procedure started on 27 February 2001.
- The Rapporteur's first Assessment Report was circulated to all CPMP members on 9 May 2001 The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on  10 May 2001
- During the meeting on 27 June 2001 the CPMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 29 June 2001.
- The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 11 October 2001.
- The Rapporteurs circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 20 November 2001
- During the meeting on 12 December 2001 the CPMP agreed on a List of Outstanding issues to be sent to the applicant. The list was sent to the applicant on 14 December 2001.
- The company submitted the responses to the CPMP  List of Outstanding Issues on 3 January 2002.
- An expert meeting was convened at the EMEA on 18 February 2002.
- During the meeting on 19-21 March 2002 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting a Marketing Authorisation to Tamiflu on 21 March 2002.
- The  CPMP  Opinion  was  forwarded  in  all  official  languages  of  the  European  Commission, which adopted the corresponding Decision on  20 June 2002.

Co-Rapporteur: Prof. Ana Cristina Sampaio